Chronic obstructive pulmonary disease (COPD) is a condition characterized by progressive airflow limitation, which causes considerable morbidity and mortality worldwide.Yet the burden of COPD is poorly recognized, and the disease remains an inadequately managed health problem. Few studies have attempted to quantify the impact of the disease on patient health, the healthcare system and society as a whole.This provided the rationale for Confronting COPD in North America and Europe, the first large-scale international survey of the burden of COPD.This paper describes how quantitative measures of healthcare resource utilization and workplace productivity loss were derived from patient responses to the Confronting COPD survey, to investigate the country-specific impact of COPD on the healthcare system and societyThe aim of this analysis is to inform countries of the economic impact of the condition, and demonstrate the need for better COPD treatment to improve health and reduce the sizeable burden of this disease.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a condition characterized by progressive airflow limitation, and is an umbrella term including chronic bronchitis and emphysema.The single most important factor associated with the development of COPD is a long-term history of smoking behaviour (I). COPD causes considerable mortality, leading to an estimated 2.7 million deaths worldwide in the year 2000 (2) .A global survey of the burden of disease ranked COPD as the sixth leading cause of death in 1990, with a predicted rise to third place by the year 2020 (3-I). COPD is the only disease among the leading causes of death that is increasing in prevalence (5) (6) . In addition to mortality, the morbidity associated with COPD places a significant burden on the patient, with debilitating symptoms and impaired quality of life (34, (7) (8) .The economic burden of the disease is borne by the healthcare system, the patient and society, resulting from extensive primary and secondary healthcare resource use and lost productivity (9-l I) .
Yet the burden of COPD is poorly recognized, and the disease remains poorly understood and inadequately managed. Surprisingly little is known about the condition beyond its clinical nature, population prevalence and mortality rate, and few studies have attempted to quantify the impact of the disease on patient health, the healthcare system and society as a whole.This provided the rationale for Confronting COPD in North America and Europe, the first large-scale international survey of the burden of COPD.Telephone interviews were completed with patients and physicians in eight countries, to collect information on symptom frequency and severity, quality of life impact, disease management, the use of healthcare resources and lost productivity. As reported in detail elsewhere, the survey confirmed the detrimental impact of COPD on patient health and quality of life (I 2-l 3). The survey also highlighted a strong need to improve recognition and knowledge of COPD among both patients and healthcare professionals, and demonstrated that COPD is, on the whole, being poorly managed with currently available treatments.
Worldwide consensus guidelines have been devised for the management of COPD (I). These guidelines provide recommendations for the effective diagnosis and treatment of patients in primary and secondary care. However, improving COPD management necessitates raising the profile of the disease with healthcare decision makers worldwide (14) . Lack of recognition means that COPD tends to receive healthcare funding at a level far below what would be expected, given the mortality and morbidity impact of the disease (15 (12) . The patient samples for the survey were identified by systematically screening geographically stratified samples of 20 I 92 I households, using random digit dialling of telephone numbers. More than 94% of the households had at least one phone line in all countries except Germany (89.3%) (24). The criteria for inclusion of patients in the survey were: l at least 45 years of age; l smoking history of at least IO years; l previously diagnosed with COPD, emphysema or chronic bronchitis or chronic bronchitis defined by persistent coughing with phlegm or sputum from the chest for the last 2 years or more (I 2).
Patients were questioned using an adaptation of the American Thoracic Society (ATS) questionnaire, a structured instrument previously validated for the measurement of asthma symptoms in the general population, with proven reliability when administered by telephone interview (25) (26) . For the purposes of this survey, additional questions were included to collect information on patient demographics, activity limitation due to COPD, healthcare contacts and the use of respiratory therapy. The Medical Research Council (MRC) scale was also added to the questionnaire, as a measure of the severity of COPD symptoms (27) ( Table I) .
The English version of the completed patient questionnaire was translated and back-translated into Dutch, French, German, Italian and Spanish, before being administered to respondents in their first language (I 2). The questionnaire took each respondent approximately 25 minutes to complete.
In all countries except Germany, patient responses to the Confronting COPD survey were used to conduct an economic analysis of the country-specific burden of COPD.The analysis included an assessment of healthcare resource use, lost productivity and associated costs, as described in detail below.
ASSESSING COPD-RELATED HEALTHCARE RESOURCE USE
Patients included in the Confronting COPD survey were asked questions about their COPD-related hospitalizations, emergency room visits, primary care consultations, treatment, and laboratory tests, for the I2-month period prior to the survey. Patient responses were used to derive quantitative measures of healthcare resource utilization, as summarized in Tables Z+.The assumptions used to convert patient responses into resource measures were discussed and agreed with key opinion leaders in each country participating in the survey. A wide range of measures was included to provide a detailed breakdown of the impact of COPD on primary and secondary care.
Information on hospital contacts was taken directly from the survey. Data was collected on the number and proportion of patients reporting hospitalization and emergency room (ER) visits, and the frequency/mean number per patient of reported inpatient stays or ER visits. To assess the frequency of health care contacts, respondents were asked to report how often they had seen a doctor about their condition, and to identify the medical speciality of the doctor seen most often ( Table 2 ). The number of patients receiving prescribed medication for COPD was obtained directly from the survey. Each patient was asked to provide the names of all drugs taken in the past year. Medications were grouped into drug classes as shown inTable 3. Bupropion was included as a drug that may be used by some COPD patients as a smoking cessation aid. The survey also collected data on the number of patients taking antibiotics for respiratory infections, the number of influenza vaccinations received, and the use of home oxygen therapy in the past I2 months (Table 3) . Finally, patients were asked to report whether their physician had arranged for any diagnostic tests or investigations to be conducted over the past I2 months, in relation to their respiratory condition (Table 4) .
MEASURING WORK LOSS DUET0 COPD
The Confronting COPD survey collected data on patient work loss due to COPD, as summarized in Table 5 . As the survey did not collect specific information on retirement, it was assumed that patients who had reached the standard retirement age in each country were no longer working (see the papers of each individual country for further information).
CALCULATING THE COST IMPACT OF COPD
The findings of the Confronting COPD survey were used to analyse the economic burden of COPD on the healthcare system and society by using local countryspecific costs. All costs were calculated in the local currency and US dollars, with the U.K. cost results also calculated in Euros. The economic analysis included direct costs (resulting from contacts with healthcare professionals, inpatient hospitalizations, emergency room visits, treatment and laboratory tests for COPD) and indirect costs (resulting from work loss in patients with COPD), to estimate the total societal cost of COPD per patient.
Direct costs
In each country, annual per patient costs of COPD were calculated for each healthcare resource measure, by multiplying the mean frequency of use by unit costs derived by local health economics experts in each country participating in the economic analysis (Table 6 ). These costs were summed to provide an estimate of the mean direct cost of COPD per patient.
Indirect and total societal costs
To assess indirect costs, unit costs of a day lost from work were adjusted for age group (45-54 years, 55-64years) and gender. The indirect costs of COPD were calculated by multiplying the mean number of days lost per patient by a unit cost for a day of lost productivity (caregiver work loss was not included in the indirect costs analysis). In the U.K., the U.S.A., Canada, France, Italy, and Spain, work loss was assessed using the human capital approach, whereby economic costs are calculated for the period from the start of illness-related work absence until the patient returns to work, or retires.The unit cost per day of work loss included both hourly wages and fringe benefits. In the Netherlands, indirect costs were calculated using the friction cost approach, as preferred by local health economists (29) . This method reduces the possibility of overestimating productivity losses, by assuming that a patient missing work due to a long period of illness is likely to be replaced by another employee, rather than the position remaining vacant until the patient is able to return to Sl9 work.A maximum productivity loss value for the average time a position remains vacant during a period of patient illness may be ascertained by interviewing employers, or estimated from job centre statistics or government labour reports. However, outside the Netherlands, the friction cost approach remains controversial and is not generally used.
Societal costs
In each country, the annual direct and indirect cost results were summed to give an estimate of the mean per patient societal cost of COPD for the survey sample.
Sub-analysis of cost results
The direct, indirect and societal costs of COPD were examined further in relation to the following patient variables: The aim of this analysis was to identify groups of patients in which the burden of COPD was disproportionately high.
Once all the data for the economic analysis had been collected, information on healthcare resource use, time lost from work, and the direct, indirect and societal costs resulting from COPD were assessed separately for each country participating in the economic analysis of the Confronting COPD survey. The aim was to provide healthcare decision makers in each country with an analysis of the burden of COPD within a typical patient population, with broader consideration of local issues such as the effectiveness of current management strategies. In this way, it was anticipated that the data would help to demonstrate the need for the improved management of patients with COPD.
DISCUSSION
The economic analysis of Confronting COPD in North America and Europe used patient responses to a telephone interview to derive quantitative measures of healthcare resource use and work loss, which were used to estimate the direct and indirect costs of the disease. The survey included patients with a diagnosis of COPD, chronic bronchitis or emphysema, and patients who remained undiagnosed despite reporting symptoms of chronic bronchitis.
RESPIRATORY MEDICINE
The survey used randomized digit dialling and stratified sampling methods to obtain a national sample of patients with COPD from the general population. The vast majority of households in each country had at least one telephone line, so population coverage was high. While small numbers of patients without a telephone (most likely those of low socioeconomic status) would be missed by this sampling method, alternative survey methods may be more likely to exclude a significant proportion of patients with COPD. For example, the selection of patients using primary care practice registers would omit patients who have symptoms of COPD, but remain undiagnosed, which could be as many as three-quarters of patients with this disease (31). Alternative methods of selecting COPD patients for surveys may include specialist referral or lung function criteria, both of which may result in the inclusion of disproportionately high numbers of patients with relatively severe disease.
The survey relied on self-report to identify patients with a diagnosis of COPD, chronic bronchitis or emphysema. All patients included in the survey were aged 45 years or older, and 99.5% of patients were current or former smokers, with at least a IO pack-year smoking history, under the rationale that COPD develops in middle-age, most commonly following a longterm history of smoking behaviour. Patients who reported a diagnosis of asthma were excluded from taking part in the survey. It is possible that some of the patients who reported a diagnosis of COPD may also have had asthma, particularly as the use of spirometry to diagnose and differentiate COPD from other respiratory conditions is underutilized by primary care practitioners in many countries (I 2), though this would also apply if patients were recruited through practice databases. The inclusion of patients with COPD, rather than asthma, in this survey is supported by differences between the clinical results of the patient questionnaire (in terms of symptoms and disability levels) compared with those of an international asthma survey conducted using similar methodology (I 2,32).
Patients with undiagnosed COPD were also included in the current survey.To reduce the possibility that these patients were suffering from other respiratory conditions, they had to meet strict symptom criteria (persistent cough with the production of phlegm or sputum from the chest for at least 2years) consistent with chronic bronchitis, as defined in international treatment guidelines for COPD.
Patient responses to the Confronting COPD survey were used to quantify the extent of healthcare resource utilization, including contacts with healthcare professionals, inpatient hospitalizations, emergency room visits, treatment and laboratory tests, during the IZmonth period prior to the survey. A number of assumptions were agreed with local key opinion leaders for the data analysis, to ensure that the interpretation of patient responses reflected patterns of resource use that are observed in practice. For example, it was assumed that patients reporting the use of medication in more than one class would be using both drugs concurrently, and that patients would only receive one influenza vaccination during the course of a year. Overall, the direct costs calculated from the survey data are likely to represent conservative estimates, as some aspects of care that are typical in patients with COPD, such as pulmonary rehabilitation services, or home visits by healthcare professionals, were not included in the patient questionnaire.
The indirect costs of COPD in the survey were calculated as the sum of the days absent from work in patients able to work, and the number of days lost in patients who were prevented from working at all during the previous year. This calculation is likely to underestimate the indirect cost of the disease, as time lost from work by the caregivers of patients with COPD was not included in the analysis. In addition, the survey was unable to assess social security/benefit costs arising from the illness and disability caused by COPD, which have been shown to have a significant impact on the economy in previous studies (33) (34) (35) . Therefore, the Confronting COPD survey probably provides a conservative estimate of the annual per patient cost of COPD to society.
The survey provided data on the prevalence rate of COPD in the population over the age of 45 years, which was estimated at around 4% for all participating countries, ranging from 3.2% in France to 5.4% in the Netherlands.
However, as might be expected, these estimates tended to be higher than those previously reported in the individual countries (I 6-23), probably as a result of the inclusion of undiagnosed patients, and the methodology used to identify patients with the disease in this survey (e.g. self-report rather than patient databases).Although it could be interesting to apply the per patient costs to non-survey estimates of the number of patients with COPD in each country, this was not included in the results of the Confronting COPD analysis, because the inclusion of undiagnosed patients in this survey may invalidate comparisons with other estimates of the total societal burden of the disease.
CONCLUSION
This paper describes the methodology behind the economic analysis of Confronting COPD in North America and Europe. Quantitative measures of healthcare resource use and lost productivity were derived from patient responses to the survey, and used to calculate the direct and indirect costs of COPD in seven individual countries. It is anticipated that the results will be useful in informing individual countries of the societal impact of COPD, and raising awareness of the need for improved management.
